Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hanmi-pharm-co-ltd" target="_blank" data-smartkarma-citation="entities:12476:1" rel="noopener">Hanmi Pharm (128940 KS)</a> has reported mixed performance for 3Q25. Despite flat topline and high R&amp;D investment, mid-single digit growth in operating profit is the key highlight of 3Q25 result.</li>
<li>Interim topline results of Phase 3 trials for efpeglenatide have raised expectations that the drug will establish itself as a "national obesity drug" based on excellent efficacy and proven safety.</li>
<li>The company submitted clinical trial application to FDA for HM17321. Hanmi received FDA approval to initiate a Phase 2 clinical trial with HM15275, which is expected to commence this month.</li>
</ul>



Hanmi Pharm (128940 KS) has reported mixed performance for 3Q25. Despite flat topline and high R&amp;D investment, mid-single digit growth in operating profit is the key highlight of 3Q25 result.
Interim topline results of Phase 3 trials for efpeglenatide have raised expectations that the drug will establish itself as a "national obesity drug" based on excellent efficacy and proven safety.
The company submitted clinical trial application to FDA for HM17321. Hanmi received FDA approval to initiate a Phase 2 clinical trial with HM15275, which is expected to commence this month.


Hanmi Pharm (128940 KS): Flagship Drugs Boost 3Q25 Result Amid Obesity Pipeline Progress

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Equity Capital Markets

<ul>
<li>Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. The IPO price range is from 9,000 won to 11,000 won per share.</li>
<li>According to the bankers' IPO price range, the expected market cap after the IPO is from 599 billion won to 732 billion won.</li>
<li>Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates into preclinical and early clinical stages.</li>
</ul>


Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. The IPO price range is from 9,000 won to 11,000 won per share.
According to the bankers' IPO price range, the expected market cap after the IPO is from 599 billion won to 732 billion won.
Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates into preclinical and early clinical stages.


Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of KRX stocks as of Sep 12th. The aggregated short interest was USD11.2bn.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Doosan Fuel Cell, HMM, Samsung Electronics, Hyundai Motor, SK Hynix.</li>
</ul>


We analyzed the changes in short interest of KRX stocks as of Sep 12th. The aggregated short interest was USD11.2bn.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Doosan Fuel Cell, HMM, Samsung Electronics, Hyundai Motor, SK Hynix.


KRX Short Interest Weekly (Sep 12th): Doosan Fuel Cell, HMM, Samsung Electronics, Hyundai Motor

<ul>
<li>We analyzed the changes in foreign holdings of KRX stocks as of Sep 12th. The aggregated holding was USD694.4bn.</li>
<li>We estimate that foreign flows to be inflows of USD1,835mln. We tabulate the league table for top changes by value for 1W/4W/1Y and top stocks held by foreign institutions.</li>
<li>We highlight changes of foreign holdings in SK Hynix, Hanwha Ocean, Samsung Electronics, kakaopay, HANWHA AEROSPACE.</li>
</ul>


We analyzed the changes in foreign holdings of KRX stocks as of Sep 12th. The aggregated holding was USD694.4bn.
We estimate that foreign flows to be inflows of USD1,835mln. We tabulate the league table for top changes by value for 1W/4W/1Y and top stocks held by foreign institutions.
We highlight changes of foreign holdings in SK Hynix, Hanwha Ocean, Samsung Electronics, kakaopay, HANWHA AEROSPACE.


KRX Foreign Holding Weekly (Sep 12th): SK Hynix, Hanwha Ocean, Samsung Electronics, Kakaopay

<ul>
<li>We analyzed the changes in foreign holdings of KRX stocks as of Aug 15th. The aggregated holding was USD653.4bn.</li>
<li>We estimate that foreign flows to be inflows of USD772mln. We tabulate the league table for top changes by value for 1W/4W/1Y and top stocks held by foreign institutions.</li>
<li>We highlight changes of foreign holdings in SK Hynix, NAVER, Samsung Electronics, Kakao, Hanwha Ocean.</li>
</ul>


We analyzed the changes in foreign holdings of KRX stocks as of Aug 15th. The aggregated holding was USD653.4bn.
We estimate that foreign flows to be inflows of USD772mln. We tabulate the league table for top changes by value for 1W/4W/1Y and top stocks held by foreign institutions.
We highlight changes of foreign holdings in SK Hynix, NAVER, Samsung Electronics, Kakao, Hanwha Ocean.


KRX Foreign Holding Weekly (Aug 15th): SK Hynix, NAVER, Samsung Electronics, Kakao, Hanwha Ocean

South Korea

Yuhan Corporation manufactures and markets various pharmaceutical products on its own and through joint ventures with other global pharmaceutical companies. The Company also produces personal care products, dietary supplements, and veterinary medicines.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Yuhan Corp (000100 KS)

Hanmi Pharm (128940 KS): Flagship Drugs Boost 3Q25 Result Amid Obesity Pipeline Progress

Hanmi Pharm reports mixed 3Q25 performance with flat topline and mid-single digit growth in operating profit. Expectations are rising on...

Tina Banerjee

Aimedbio IPO Preview

Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates...

Douglas Kim

KRX Short Interest Weekly (Sep 12th): Doosan Fuel Cell, HMM, Samsung Electronics, Hyundai Motor

We analyzed KRX short interest report for the past week and highlighted short interest changes in Doosan Fuel Cell, HMM, Samsung Electronics,...

Ke Yan, CFA, FRM

KRX Foreign Holding Weekly (Sep 12th): SK Hynix, Hanwha Ocean, Samsung Electronics, Kakaopay

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in SK Hynix, Hanwha Ocean, Samsung Electronics,...

Ke Yan, CFA, FRM

KRX Foreign Holding Weekly (Aug 15th): SK Hynix, NAVER, Samsung Electronics, Kakao, Hanwha Ocean

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in SK Hynix, NAVER, Samsung Electronics, Kakao,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Hanmi Pharm (128940 KS): Flagship Drugs Boost 3Q25 Result Amid Obesity Pipeline Progress

​Hanmi Pharm reports mixed 3Q25 performance with flat topline and mid-single digit growth in operating profit. Expectations are rising on...

Tina Banerjee

Aimedbio IPO Preview

Aimedbio is getting ready to complete its IPO in KOSDAQ in November 2025. Aimedbio has advanced multiple antibody-drug conjugates (ADC) candidates...

Douglas Kim

KRX Short Interest Weekly (Sep 12th): Doosan Fuel Cell, HMM, Samsung Electronics, Hyundai Motor

We analyzed KRX short interest report for the past week and highlighted short interest changes in Doosan Fuel Cell, HMM, Samsung Electronics,...

Ke Yan, CFA, FRM

KRX Foreign Holding Weekly (Sep 12th): SK Hynix, Hanwha Ocean, Samsung Electronics, Kakaopay

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in SK Hynix, Hanwha Ocean, Samsung Electronics,...

Ke Yan, CFA, FRM

KRX Foreign Holding Weekly (Aug 15th): SK Hynix, NAVER, Samsung Electronics, Kakao, Hanwha Ocean

We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in SK Hynix, NAVER, Samsung Electronics, Kakao,...

Ke Yan, CFA, FRM

Hanmi Pharm reports mixed 3Q25 performance with flat topline and mid-single digit growth in operating profit. Expectations are rising on...